Chemical and Physiological Relevance of Glucose Degradation Products in Peritoneal Dialysis

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 181-185

  Mittelmaier, Stefan ^a   Niwa, Toshimitsu ^b   Pischetsrieder, Monika ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEOXYGALACTOSONE; 3 DEOXYGLUCOSONE; 3,4 DIDEOXYGLUCOSONE 3 ENE; 3,4-DIDEOXYGLUCOSONE-3-ENE; 3-DEOXYGALACTOSONE; 3-DEOXYGLUCOSONE; DEOXYGLUCOSE; DIALYSIS FLUID; DRUG DERIVATIVE; GALACTOSE; GLUCOSE; GLUCOSONE; GLYOXAL; KETOSE; PYRONE DERIVATIVE;

ARTICLE; CHEMISTRY; HEAT; HUMAN; PERITONEAL DIALYSIS; STRUCTURE ACTIVITY RELATION;

DEOXYGLUCOSE; DIALYSIS SOLUTIONS; GALACTOSE; GLUCOSE; GLYOXAL; HOT TEMPERATURE; HUMANS; KETOSES; PERITONEAL DIALYSIS; PYRONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855169674     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.014     Document Type: Article

References (21)

1. Williams J.D., Craig K.J., Topley N., et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002, 13:470-479.
2. Frischmann M., Spitzer J., Fünfrocken M., et al. Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids. Biomed Chromatogr 2009, 23:843-851.
3. Perl J., Nessim S.J., Bargman J.M. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?. Kidney Int 2011, 79:814-824.
4. Williams J.D., Topley N., Craig K.J., et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004, 66:408-418.
5. Lee H.Y., Park H.C., Seo B.J., et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005, 25:248-255.
6. Tauer A., Knerr T., Niwa T., et al. Invitro formation of N[epsilon]-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001, 280:1408-1414.
7. Mortier S., Faict D., Schalkwijk C.G., Lameire N.H., DeVriese A.S. Long-term exposure to new peritoneal dialysis solutions: effects onthe peritoneal membrane. Kidney Int 2004, 66:1257-1265.
8. Nakamura S., Tachikawa T., Tobita K., et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003, 41(suppl 1):S61-S67.
9. Tauer A., Bender T.O., Fleischmann E.H., Niwa T., Jorres A., Pischetsrieder M. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis. Mol Nutr Food Res 2005, 49:710-715.
10. Li H., Nakamura S., Miyazaki S., et al. N2-carboxyethyl-2'-deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patients. Kidney Int 2006, 69:388-392.
11. ter Wee P.M., Beelen R.H., van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int Suppl 2003, 88:S75-S83.
12. Wieslander A.P., Nordin M.K., Kjellstrand P.T., Boberg U.C. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991, 40:77-79.
13. Lai K.N., Leung J.C., Chan L.Y., et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004, 138:466-475.
14. Ishikawa N., Miyata T., Ueda Y., et al. Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 2003, 63:331-339.
15. Nakamura S., Li H., Adijiang A., Pischetsrieder M., Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 2007, 22:2165-2174.
16. Zimmeck T., Tauer A., Fuenfrocken M., Pischestrieder M. How to reduce 3-deoxyglucosone and acetaldehyde in peritoneal dialysis fluids. Perit Dial Int 2002, 22:350-356.
17. Ueda Y., Miyata T., Goffin E., et al. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 2000, 58:2518-2524.
18. Shapira A., Shazman A., Ungar Y., Shimoni E. Reducing the formation of glucose degradation products in peritoneal dialysis solutions by ultrahigh temperature ohmic heating. Mol Nutr Food Res 2007, 51:473-478.
19. Mittelmaier S., Fünfrocken M., Fenn D., Pischetsrieder M. 3-Deoxygalactosone, a new glucose degradation product in peritoneal dialysis fluids: identification, quantification by HPLC/DAD/MSMS and its pathway of formation. Anal Bioanal Chem 2011, 399:1689-1697.
20. Mittelmaier S., Fünfrocken M., Fenn D., Fichert T., Pischetsrieder M. Identification and quantification of the glucose degradation product glucosone in peritoneal dialysis fluids by HPLC/DAD/MSMS. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:877-882.
21. Mittelmaier S., Fünfrocken M., Fenn D., Berlich R., Pischetsrieder M. Quantification of the six major α-dicarbonyl contaminants in peritoneal dialysis fluids by UHPLC/DAD/MSMS. Anal Bioanal Chemr 2011, 401:1183-1193.